FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells

Cardiovascular Research

Volumn 77, Issue 3, 2008, Pages 560-569

  Zhang, Qiuhong ^a   He, Fengtian ^a   Kuruba, Ramalinga ^a   Gao, Xiang ^a   Wilson, Annette ^b   Li, Jiang ^a   Billiar, Timothy R ^c   Pitt, Bruce R ^b   Xie, Wen ^a   Li, Song ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin II type 2 receptor; FXR; Regulation; Smooth muscle cells

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALPHA BROMO 4 HYDROXYACEPHENONE 4 HYDROXYPHENACYL BROMIDE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSINOGEN; FARNESOID X RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REPORTER GENE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASCULAR LESION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; CHENODEOXYCHOLIC ACID; DNA-BINDING PROTEINS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; ISOXAZOLES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROMOTER REGIONS (GENETICS); PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 38849135894     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm068     Document Type: Article

References (51)

1. Dostal DE, Baker KM. The cardiac Renin-Angiotensin system: conceptual, or a regulator of cardiac function. Circ Res 1999;85:643-650.
2. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52:639-672.
3. Barnes WG, Reiter E, Violin JD, Ren XR, Milligan G, Lefkowitz RJ. Beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem 2005;280:8041-8050.
4. Cosentino F, Savoia C, De Paolis P, Francia P, Russo A, Maffei A et al. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 2005;18:493-499.
5. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 2006;24:2417-2422.
6. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
7. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides 2005;26:1401-1409.
8. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005;45:840-844.
9. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266.
10. Azizi M. Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists. Rev Prat 2004;54:1167- 1174.
11. Haxsen V, Adam-Stitah S, Ritz E, Wagner J. Retinoids inhibit the actions of angiotensin II on vascular smooth muscle cells. Circ Res 2001;88:637-644.
12. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
13. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005;288:H1037-H1043.
14. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000;102:1834-1839.
15. Takeda K, Ichiki T, Funakoshi Y, Ito K, Takeshita A. Downregulation of angiotensin II type 1 receptor by all-trans retinoic acid in vascular smooth muscle cells. Hypertension 2000;35:297-302.
16. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81:687-693.
17. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-1365.
18. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443-463.
19. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-1418.
20. Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 2005;433:397-412.
21. Kuipers F, Claudel T, Sturm E, Staels B. The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism. Rev Endocr Metab Disord 2004;5:319-326.
22. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103:1006-1011.
23. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 2004;101:3668-3673.
24. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 2006;98:192-199.
25. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000;43:2971-2974.
26. Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 2001;98:3375-3380.
27. Kocarek TA, Shenoy SD, Mercer-Haines NA, Runge-Morris M. Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes. J Pharmacol Toxicol Methods 2002;47:177-187.
28. Bishop-Bailey D, Larkin SW, Warner TD, Chen G, Mitchell JA. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol 1997;121:125-133.
29. Saini SP, Sonoda J, Xu L, Toma D, Uppal H, Mu Y et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 2004;65:292-300.
30. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:289-303.
31. Shimamoto Y, Ishida J, Yamagata K, Saito T, Kato H, Matsuoka T et al. Inhibitory effect of the small heterodimer partner on hepatocyte nuclear factor-4 mediates bile acid-induced repression of the human angiotensinogen gene. J Biol Chem 2004;279:7770-7776.
32. Podvinec M, Kaufmann MR, Handschin C, Meyer UA. NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol Endocrinol 2002;16:1269-1279.
33. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG et al. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004;61:159-168.
34. Stoll M, Unger T. Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 2001;99:175-182.
35. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000;275:10638-10647.
36. Song CS, Echchgadda I, Baek BS, Ahn SC, Oh T, Roy AK et al. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J Biol Chem 2001;276:42549-42556.
37. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277:2908-2915.
38. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003;278:25468-25480.
39. Li J, Wilson A, Kuruba R, Zhang QH, Gao X, He FT et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res 2007;77:169-177.
40. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996;93:156-160.
41. Huang XC, Richards EM, Sumners C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem 1996;271:15635-15641.
42. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD et al. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 1997;325:449-454.
43. Hernandez Schulman I, Zhou MS, Raij L. Cross-talk between Angiotensin II receptor Types 1 and 2: potential role in vascular remodeling in humans. Hypertension 2007;9:270-271.
44. Nakajima M, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 receptor antagonizes the growth effects of the AT1 receptor: gain of function study using in vivo gene transfer. Proc Natl Acad Sci USA 1995;92:10663-10667.
45. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8-13.
46. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007;49:341-346.
47. Molavi B, Chen J, Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 2006;291:H687-H693.
48. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 2007;28:236-243.
49. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 2005;46:2595-2604.
50. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2006;26:2316-2321.
51. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 2006;1761:1401-1409.